New drug sponsors with March review goals are now on notice that a continued government shutdown may affect their applications, as the agency begins demonstrating how a user fee program will function absent appropriations and carryover funds.
Remaining carryover prescription drug user fee funds currently sustaining many product review activities are expected to run out between Feb....